This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here


CLEVELAND, June 24, 2013 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced its next generation clinical trial management enterprise resource planning (ERP) solution. The D ATATRAK ONE C LINICAL ERP™ release streamlines the clinical trial process through enhancements to D ATATRAK's single database architecture. Data is now informational, actionable and visible for faster, better decision making.

(Logo: )

The DATATRAK ONE CLINICAL ERP™ solution is designed with a new, more intuitive user interface providing improved workflows and mobility. The global, real-time view of data enables users to proactively identify and address concerns that result in higher quality and operational efficiencies throughout the drug development process.

"With the revolutionary D ATATRAK ONE C LINICAL ERP™ release, D ATATRAK has set the new standard for eClinical solutions," stated Laurence P. Birch, D ATATRAK's Chairman of the Board and CEO. "Users are now able to configure their desktop and workflows to reflect their personal preferences as well as display the data, tasks and reports that are pertinent during each phase of the study. Essentially, users can continuously customize their views and user preferences to facilitate the collection, cleaning and submission of clinical data, thus creating the most advanced user experience in eClinical solutions today."

In addition to the release of the D ATATRAK ONE C LINICAL ERP™ solution, D ATATRAK is demonstrating uPRO, its new patient reported outcomes solution and uEDC's new Partial Metadata functionality.

The D ATATRAK ONE™ suite of products empowers Sponsors and CROs to efficiently design, deliver and manage clinical trials. The unified, end-to-end clinical research offering extends the D ATATRAK ONE C LINICAL ERP™ system by providing a comprehensive suite of seven products – all sold standalone or together and delivered globally in a secure cloud: uCTMS, uDesign, uEDC, uIRT, uPRO, uSafety and uTrain

Join D ATATRAK Thought Leaders:

Tweet: D ATATRAK ONE C LINICAL ERP™ Introduction 

About D ATATRAK D ATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. D ATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via D ATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The D ATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 15, 2013 announcing its results for the first quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,068.79 +18.04 0.11%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,813.5790 +2.7910 0.06%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs